Revenue segments as reported by the company.

Software products and services

Drug discovery

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Schrodinger 

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Schrodinger reports robust revenue growth and eyes strategic expansion

Schrodinger delivered strong financial performance in 2022, driven by revenue growth in software and drug discovery segments.
The company's innovative pipeline advancements and focus on neuroscience therapeutics position it well for future growth.
While facing challenges in operating expenses and revenue projections, Schrodinger has opportunities for expansion through partnerships and customer growth.
Capitalizing on existing strengths and addressing challenges will be key for Schrodinger to sustain its growth trajectory and competitive edge.

Schrodinger (SDGR) reports robust Q1 performance and growth opportunities

Schrodinger (SDGR) had a strong Q1 2023, with revenue growth driven by software and drug discovery collaborations.
The company's balance sheet strengthened, but challenges exist with smaller biopharma revenue mix and customer acquisition.
Opportunities lie in capitalizing on existing customer loyalty, potential revenue growth, and continued investments in technology.
Overall, Schrodinger is well-positioned to leverage its strengths and address challenges to drive future growth.

Schrodinger meets revenue expectations, focuses on AI-driven drug discovery

Schrodinger's Q2 2023 earnings call highlighted solid revenue performance, ongoing software revenue discussions, and investments in R&D for platform development. The company showcased strengths in innovative drug discovery methods, progress on proprietary programs, and FDA clearances. Challenges include revenue fluctuations and uncertainties in revenue projections, while opportunities lie in expanding software contracts and leveraging AI for efficiency.

Schrodinger reports solid Q3 growth amidst expense challenges and opportunities

Schrodinger's Q3 performance showed revenue growth driven by software and drug discovery segments, despite increased expenses.
The company's focus on operational efficiency and proprietary programs positions it well for future growth and market expansion.
While facing challenges in managing expenses and uncertainties in partner priorities, Schrodinger remains committed to innovation and value creation.
Opportunities lie in scaling up software usage, evaluating collaboration programs, and leveraging customer interest for revenue growth.

Schrodinger reports strong revenue growth and strategic collaborations in 2023

Schrodinger's financial performance in 2023 reflects growth in total revenue and software revenue, driven by customer expansions and program advancements.
The company's strengths lie in its strategic focus on global biopharma companies, collaborations for AI tools, and the trend towards hosted contracts.
Challenges include forecasting revenue growth, decision-making on program advancement, and factors influencing software revenue dynamics.
Opportunities exist in the increased demand for computational tools, ongoing discussions for software adoption, and the validation of the platform through collaborations.

Schrodinger reports Q1 revenue growth amidst challenges and collaboration opportunities

Schrodinger's Q1 2024 performance reflects revenue growth driven by software revenue, though challenges in China and decreased gross margin were noted.
The company's strengths lie in regained rights to key inhibitors, promising pipeline advancements, and potential growth in ACV and collaboration opportunities.
While facing challenges in profitability and R&D expenses, Schrodinger is well-positioned to capitalize on opportunities in collaborations, funding, and drug development.
Overall, Schrodinger's strategic focus on innovation, partnerships, and pipeline advancement sets the stage for future growth and market expansion.

Schrodinger reports solid Q2 results, eyes strategic growth opportunities

Schrodinger's Q2 performance reflects steady revenue growth and margin improvement, despite operational challenges.
Strategic partnerships, acquisitions, and innovative solutions position Schrodinger for future expansion and market leadership.
Efforts to control expenses, drive revenue growth, and leverage market opportunities will be crucial for Schrodinger's long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corporacion America Airports

DHT Holdings

Embark Technology

El Pollo Loco

 CareCloud

Velodyne Lidar

When compiling my small-cap stock picks, I tried to choose names that seemed to be benefiting from this new, more “risk-on” environment. Among the encouraging features of the August Consumer Price Index report were the 0.1% month-over-month increase in the headline number and the deceleration of the year-over-year CPI to 8.3% from 8.5% in July, Additionally, the increase in the labor participation rate last month should put downward pressure on wages.

7 Small-Cap Stock Picks to Beat the September Market Slump

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at Citi's 17th Annual BioPharma Conference.

Schrödinger to Present at Citi's 17th Annual BioPharma Conference

Schrödinger reported mixed Q2 earnings with a miss on EPS and a beat on revenue. The company experienced strong performance across both aspects of the company business. The company revealed another quarter of substantial growth. I believe the earnings report supports the growth narrative.

Schrödinger: Q2 Earnings Supports Growth Narrative

NEW YORK--(BUSINESS WIRE)--Schrödinger reports inducement grants to newly appointed chief financial officer, Geoffrey Porges, MBBS.

Schrödinger Reports Inducement Grants To Newly Appointed Chief Financial Officer

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer.

Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

Schrodinger, Inc. (NASDAQ:SDGR ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Jaren Madden - SVP, IR & Corporate Communications Ramy Farid - CEO, President & Director Jenny Herman - SVP, Finance & Corporate Controller Karen Akinsanya - President, Research & Development Therapeutics Conference Call Participants Michael Ryskin - Bank of America Merrill Lynch Gary Nachman - BMO Capital Markets Vikram Purohit - Morgan Stanley Operator Thank you for standing by. Welcome to Schrödinger's conference call to review second quarter 2022 financial results.

Schrodinger, Inc. (SDGR) CEO Ramy Farid on Q2 2022 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the second quarter of 2022.

Schrödinger Reports Second Quarter 2022 Financial Results

Bilibili

Zhihu

Zai Lab Ltd.

SHANGHAI , July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price is CNY 18.12 per share, representing a market cap of CNY 10.419 billion.

Qiming's Portfolio Company InventisBio Lists on STAR Market

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will report second quarter 2022 financial results on August 4.

Schrödinger to Announce Second Quarter 2022 Financial Results on August 4

GlaxoSmithKline

Biotech stocks have rebounded lately and are poised to keep surging, so it's a good time to buy biotech stocks on the dip. The post 3 Biotech Stocks to Buy on the Dip appeared first on InvestorPlace.

3 Biotech Stocks to Buy on the Dip

Amazon

Bionano Genomics

Freeport-McMoRan

General Electric

Rivian Automotive

Shoals Technologies Group

With the stock market pricing in a recession that likely won't arrive anytime soon, these are some of the best stocks to buy on a dip. The post The 7 Best Stocks to Buy on a Dip in July appeared first on InvestorPlace.

The 7 Best Stocks to Buy on a Dip in July

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced FDA clearance of investigational new drug application for SGR-1505, a MALT1 inhibitor.

Schrödinger Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor

NEW YORK--(BUSINESS WIRE)--Schrödinger convenes global educators for second annual Educator's Day.

Schrödinger Convenes Global Educators For Second Annual Educator's Day

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at the Jefferies Healthcare Conference.

Schrödinger to Present at Jefferies Healthcare Conference

NEW YORK--(BUSINESS WIRE)---- $SDGR--Schrödinger announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022.

Schrödinger Announces Appointment of Arun Oberoi to Board of Directors

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at Citi Biotech Virtual Co-Panel Day.

Schrödinger to Present at Citi Biotech Virtual Co-Panel Day

Schrödinger, Inc. (NASDAQ:SDGR ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Jaren Madden – Senior Vice President of Investor Relations and Corporate Affairs Ramy Farid – Chief Executive Officer Jenny Herman – Senior Vice President of Finance and Corporate Controller Karen Akinsanya – President of R&D, Therapeutics Conference Call Participants Vikram Purohit – Morgan Stanley David Lebowitz – Citi Andrew Tsai – Jefferies Gaurav Goparaju – Berenberg Capital Operator Welcome to Schrödinger's Conference Call to review First Quarter 2022 Financial Results. My name is Charlie, and I'll be your operator for today's call.

Schrödinger's (SDGR) CEO Ramy Farid on Q1 2022 Results - Earnings Call Transcript

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 12.73% and 36.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported first quarter 2022 financial results.

Schrödinger Reports First Quarter 2022 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported it will announce first quarter 2022 financial results on May 4.

Schrödinger to Announce First Quarter 2022 Financial Results on May 4

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported new preclinical data supporting advancement of its Wee1 Inhibitor Program at AACR 2022 Annual Meeting.

Schrödinger Reports New Preclinical Data Supporting Advancement of Its Wee1 Inhibitor Program at American Association of Cancer Research 2022 Annual Meeting

EVgo

Pubmatic

These hypergrowth stocks are bargains after retreating for much of the last year. They will all perform very well for long-term investors.

3 Hypergrowth Tech Stocks to Buy for Huge Upside Potential

Schrödinger software platform makes it chiefly a healthcare technology company; however, the company is developing an impressive pipeline and list partners from their drug discovery efforts.

Schrödinger: Holding The Keys To Discovery

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present new preclinical data from its Wee1 Inhibitor Program at AACR Annual Meeting 2022.

Schrödinger To Present New Preclinical Data From Its Wee1 Inhibitor Program At AACR Annual Meeting 2022

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at Truist Securities Life Sciences AI Symposium - Biotech & Tools.

News for Schrodinger Stock (SDGR)